Centre for Rare Diseases members

Ozelo MC, Luciani M, Glosli H, Kavakli K, Samji N, Makris GC, Tueckmantel C, Enriquez MM, Oliveira LC, Gupta S, Arbesú MG, Davoli M, Chan AKC, Mancuso ME (2026)
Plain Language Summary on Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa-PROTECT Main Study
Eur J Haematol (in press)
DOI 10.1111/ejh.70078, PubMed 41531337

Ozelo MC, Luciani M, Glosli H, Kavakli K, Samji N, Makris GC, Tueckmantel C, Maas Enriquez M, Oliveira LC, Gupta S, Arbesú MG, Davoli M, Chan AKC, Mancuso ME (2026)
Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa-PROTECT Main Study
Eur J Haematol (in press)
DOI 10.1111/ejh.70059, PubMed 41486550

Iversen IA, Alaerts K, Bakermans-Kranenburg M, Becker B, Blair RJ, Bartz JA, Connelly JJ, Ditzen B, Ebner NC, Kang H, Lawson EA, Lønfeldt NN, Moerkerke M, Montag C, Mora-Jensen AC, Horta M, Peled-Avron L, Procyshyn TL, Sartorius AI, Scheele D, Schneider E, Theofanopoulou C, Yamasue H, Quintana DS (2025)
The active monitoring of oxytocin research evidence (AMORE) platform
Psychoneuroendocrinology, 185, 107713 (in press)
DOI 10.1016/j.psyneuen.2025.107713, PubMed 41389446